Sign in

    Jacob Thaysen

    Chief Executive Officer at Illumina Inc
    Board
    Since September 25, 2023
    Age
    48 years
    Education
    Holds an M.Sc. and Ph.D. in Physics from the Technical University of Denmark.
    Tenure
    Joined ILMN on September 25, 2023, serving as Chief Executive Officer and member of the Board of Directors.

    Also at Illumina Inc

    CR
    Carissa Rollins
    Chief Information Officer (CIO)
    KP
    Kevin Pegels
    Chief of Global Operations
    PL
    Patricia Leckman
    Chief People Officer

    About

    Born in 1975 and currently 48, the executive has built a robust foundation in the life sciences with extensive education, earning both a Master of Science and a Ph.D. in Physics from the Technical University of Denmark.

    Beginning a career over 20 years ago, they have held pivotal roles including founder and Chief Technology Officer at a research and development company, positions at a Danish cancer diagnostics firm, and senior leadership roles at Agilent Technologies where significant operational improvements were achieved.

    Joining ILMN on September 25, 2023, in the role of Chief Executive Officer and as a Board member, the executive now leads efforts in advancing genomics and DNA sequencing technologies to improve human health.

    $ILMN Performance Under Jacob Thaysen

    Past Roles

    OrganizationRoleDate RangeDetails
    Agilent Technologies SVP, President of Life Sciences & Applied Markets Group 2018–2023 N/A
    Agilent Technologies SVP, President of Diagnostics & Genomics Group 2014–2018 N/A
    Agilent Technologies VP, General Manager, Diagnostics & Genomics 2013–2014 N/A
    Dako Corporate Vice President, R&D 2010–2013 N/A

    External Roles

    OrganizationRoleDate RangeDetails
    ALDA (Analytical, Life Science & Diagnostics Association) Chair Since 2023 N/A

    Fixed Compensation

    Data from  FY 2023
    Component NameAmountPayment ScheduleAdditional Details
    Base Salary$1,000,000 Annual Annual salary for 2023.
    Cash Make-Whole$500,000 Conditional payout Subject to clawback if resigns or terminated for cause within 2 years.
    Equity Make-Whole$3,500,000 Structured/Conditional Composed of 70% PSUs and 30% RSUs.
    ILMN Stock MatchingUp to $1,000,000 in RSUs Based on purchase timing Matches open-market ILMN shares purchased within 12 months; cliff-vests on the 3rd anniversary, subject to continued employment and share holding.
    RSUs 2023 Grant7,531 shares, $1,050,047 in value Grant Date: October 5, 2023 RSU grant details for 2023.
    All Other Compensation$46,630 Other Includes various other compensations not specified in detail.

    Performance Compensation

    Data from  FY 2023

    Performance Stock Units (PSUs) Details

    Metric (Unit/Scale)ValueAdditional Details
    Grant DateOctober 5, 2023 Date of PSU award.
    Grant Date Fair Value$2,844,553 Total fair value of the PSU grant.
    Performance MetricRelative Total Shareholder Return (rTSR) Measured against select companies in the Nasdaq Biotechnology Index.
    Performance Period3 years, ending December 28, 2025 PSU performance period duration.
    Threshold8,786 shares Minimum performance level required for any payout.
    Target17,572 shares Base performance target to achieve full award.
    Maximum30,751 shares Cap on the payout set at 175% of the target.
    Vesting ScheduleVests at end of performance period Vesting based on attainment of rTSR goals and continued employment.
    Additional ConditionsIncentives aligned with stockholder interests Payout ranges from 0% to 175% based on rTSR performance.